Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications
Atherosclerosis plaques caused by cerebrovascular and coronary artery disease have been the leading cause of death and morbidity worldwide. Precise assessment of the degree of atherosclerotic plaque is critical for predicting the risk of atherosclerosis plaques and monitoring postinterventional outc...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.906512/full |
| _version_ | 1797995936929021952 |
|---|---|
| author | Xue Li Menglin Wu Jiang Li Qi Guo Yang Zhao Xuening Zhang |
| author_facet | Xue Li Menglin Wu Jiang Li Qi Guo Yang Zhao Xuening Zhang |
| author_sort | Xue Li |
| collection | DOAJ |
| description | Atherosclerosis plaques caused by cerebrovascular and coronary artery disease have been the leading cause of death and morbidity worldwide. Precise assessment of the degree of atherosclerotic plaque is critical for predicting the risk of atherosclerosis plaques and monitoring postinterventional outcomes. However, traditional imaging techniques to predict cardiocerebrovascular events mainly depend on quantifying the percentage reduction in luminal diameter, which would immensely underestimate non-stenotic high-risk plaque. Identifying the degree of atherosclerosis plaques still remains highly limited. vNanomedicine-based imaging techniques present unique advantages over conventional techniques due to the superior properties intrinsic to nanoscope, which possess enormous potential for characterization and detection of the features of atherosclerosis plaque vulnerability. Here, we review recent advancements in the development of targeted nanomedicine-based approaches and their applications to atherosclerosis plaque imaging and risk stratification. Finally, the challenges and opportunities regarding the future development and clinical translation of the targeted nanomedicine in related fields are discussed. |
| first_indexed | 2024-04-11T10:09:35Z |
| format | Article |
| id | doaj.art-762f21114c454d86b30833acda0b0460 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T10:09:35Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-762f21114c454d86b30833acda0b04602022-12-22T04:30:09ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.906512906512Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implicationsXue LiMenglin WuJiang LiQi GuoYang ZhaoXuening ZhangAtherosclerosis plaques caused by cerebrovascular and coronary artery disease have been the leading cause of death and morbidity worldwide. Precise assessment of the degree of atherosclerotic plaque is critical for predicting the risk of atherosclerosis plaques and monitoring postinterventional outcomes. However, traditional imaging techniques to predict cardiocerebrovascular events mainly depend on quantifying the percentage reduction in luminal diameter, which would immensely underestimate non-stenotic high-risk plaque. Identifying the degree of atherosclerosis plaques still remains highly limited. vNanomedicine-based imaging techniques present unique advantages over conventional techniques due to the superior properties intrinsic to nanoscope, which possess enormous potential for characterization and detection of the features of atherosclerosis plaque vulnerability. Here, we review recent advancements in the development of targeted nanomedicine-based approaches and their applications to atherosclerosis plaque imaging and risk stratification. Finally, the challenges and opportunities regarding the future development and clinical translation of the targeted nanomedicine in related fields are discussed.https://www.frontiersin.org/articles/10.3389/fphar.2022.906512/fullatherosclerosisvulnerable plaquesatherosclerosis molecular imagingtargeted nanoparticle-based contrast agentsimaging biomarkers |
| spellingShingle | Xue Li Menglin Wu Jiang Li Qi Guo Yang Zhao Xuening Zhang Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications Frontiers in Pharmacology atherosclerosis vulnerable plaques atherosclerosis molecular imaging targeted nanoparticle-based contrast agents imaging biomarkers |
| title | Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications |
| title_full | Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications |
| title_fullStr | Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications |
| title_full_unstemmed | Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications |
| title_short | Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications |
| title_sort | advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications |
| topic | atherosclerosis vulnerable plaques atherosclerosis molecular imaging targeted nanoparticle-based contrast agents imaging biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.906512/full |
| work_keys_str_mv | AT xueli advancedtargetednanomedicinesforvulnerableatherosclerosisplaqueimagingandtheirpotentialclinicalimplications AT menglinwu advancedtargetednanomedicinesforvulnerableatherosclerosisplaqueimagingandtheirpotentialclinicalimplications AT jiangli advancedtargetednanomedicinesforvulnerableatherosclerosisplaqueimagingandtheirpotentialclinicalimplications AT qiguo advancedtargetednanomedicinesforvulnerableatherosclerosisplaqueimagingandtheirpotentialclinicalimplications AT yangzhao advancedtargetednanomedicinesforvulnerableatherosclerosisplaqueimagingandtheirpotentialclinicalimplications AT xueningzhang advancedtargetednanomedicinesforvulnerableatherosclerosisplaqueimagingandtheirpotentialclinicalimplications |